MedTrace Logo

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

NCT00006401 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 793

Last updated 2015-10-06

No results posted yet for this study

Summary

To determine whether or not inhaled nitric oxide (iNO) safely decreases the incidence of chronic lung disease (CLD) in premature infants.

Conditions

  • Lung Diseases
  • Bronchopulmonary Dysplasia

Interventions

DRUG

iNO

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

OTHER

Placebo

Inhaled Nitrogen

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • John P. Kinsella, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2005-09-30
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006401 on ClinicalTrials.gov